Pieter Sonneveld, MD, PhD, a world-leading expert in multiple myeloma, is a current Professor of Hematology at the Erasmus University of Rotterdam and Erasmus Medical Center, Rotterdam, Netherlands, where he was also Head of Department from 2011-2017. He obtained his medical degree from the Erasmus University in 1977, before completing a PhD in doxorubicin pharmacology in acute leukemia. Prof. Sonneveld received a Forgaty fellowship and went on to work at the National Cancer Institute, Bethesda, MD.
Prof. Sonneveld is chairman of the HOVON Multiple Myeloma Working Group and the European Myeloma Network, and coordinates myeloma clinical trials for both groups. He has published over 500 peer-reviewed articles and served on the editorial boards of Blood, Leukemia, the European Journal of Cancer and Haematologica. Prof. Sonneveld’s work has been recognized with multiple awards, including the prestigious International Robert Kyle Lifetime Achievement Award in 2015 and the Hubertus Wald Award for Cancer Research in 2019.
Speaking on clinical and translational research in myeloma treatment and diagnostics
Prof. Sonneveld is a recognized leader in myeloma research. His work focuses on the clinical and translational facets of myeloma therapy and diagnostics. Prof. Sonneveld participates in many clinical trials in this area. His institute has been heavily involved in the development of molecular diagnostic and prognostic systems in multiple myeloma.